105 related articles for article (PubMed ID: 11785953)
1. Truncated vitronectins: binding to immobilized fibrin and to fibrin clots, and their subsequent interaction with cells.
Schvartz I; Seger D; Maik-Rachline G; Kreizman T; Shaltiel S
Biochem Biophys Res Commun; 2002 Jan; 290(2):682-9. PubMed ID: 11785953
[TBL] [Abstract][Full Text] [Related]
2. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
3. Localization of protein kinase A and vitronectin in resting platelets and their translocation onto fibrin fibers during clot formation.
Morgenstern E; Gnad U; Preissner KT; Dierichs R; Belleli A; Chestukhin A; Schvartz I; Shaltiel S
Eur J Cell Biol; 2001 Jan; 80(1):87-98. PubMed ID: 11211939
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
5. The PKA phosphorylation of vitronectin: effect on conformation and function.
Schvartz I; Kreizman T; Brumfeld V; Gechtman Z; Seger D; Shaltiel S
Arch Biochem Biophys; 2002 Jan; 397(2):246-52. PubMed ID: 11795878
[TBL] [Abstract][Full Text] [Related]
6. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
7. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
[TBL] [Abstract][Full Text] [Related]
8. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
[TBL] [Abstract][Full Text] [Related]
9. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
10. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
11. Goat vitronectin: characterization and binding to Staphylococcus aureus.
Mahawar M; Joshi P
Comp Biochem Physiol B Biochem Mol Biol; 2008 Mar; 149(3):410-8. PubMed ID: 18055240
[TBL] [Abstract][Full Text] [Related]
12. pH-induced conformation changes of adsorbed vitronectin maximize its bovine aortic endothelial cell binding ability.
Bernards MT; Jiang S
J Biomed Mater Res A; 2008 Nov; 87(2):505-14. PubMed ID: 18186064
[TBL] [Abstract][Full Text] [Related]
13. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
14. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function.
Chavakis T; Pixley RA; Isordia-Salas I; Colman RW; Preissner KT
J Biol Chem; 2002 Sep; 277(36):32677-82. PubMed ID: 12082110
[TBL] [Abstract][Full Text] [Related]
15. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
[TBL] [Abstract][Full Text] [Related]
16. Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex.
Singh B; Jalalvand F; Mörgelin M; Zipfel P; Blom AM; Riesbeck K
Mol Microbiol; 2011 Jul; 81(1):80-98. PubMed ID: 21542857
[TBL] [Abstract][Full Text] [Related]
17. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
18. The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Kamikubo Y; Kroon G; Curriden SA; Dyson HJ; Loskutoff DJ
Biochemistry; 2006 Mar; 45(10):3297-306. PubMed ID: 16519524
[TBL] [Abstract][Full Text] [Related]
19. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
Doolittle RF; Pandi L
Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
[TBL] [Abstract][Full Text] [Related]
20. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
Stringer HA; Pannekoek H
J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
